Skip to main content

Table 1 Patient baseline characteristics and transplant details

From: Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience

Total number of adult patients

70

Median (range) age (years)

35.9 (19–59)

Gender (%)

57 (81.4%) female

Disease subtype

67 (95.7%) diffuse

Median (range) disease duration (years)a

2 (1–7)

Organ involvement:

 Skin n (%)

70/70 (100%)

 Interstitial lung disease, n (%)

59/70 (84.2%)

 Pulmonary hypertension, n (%)

4/70 (5.7%) mild

 Heart involvement, n (%)

32/70 (45.7%)b

 Gastrointestinal, n (%)

57/62 (92%)

 Kidney n

0

 Positive anti-SCl70 antibodies, n (%)

43/64 (67.2%)

Previous immunosuppressive treatment:

 Methotrexate, n (%)

26/70 (37.1%)

 Cyclophosphamide, n (%)

48/70 (68.6%)

 Mycophenolate mofetil, n (%)

13/70 (18.6%)

 Rituximab, n (%)

4/70 (5.7%)

Transplant regimen:

 Cyclophosphamide + ATG

65 (92.8%)

 Fludarabine + Melphalan + ATG

5 (7.2%)

  1. Baseline (pre-transplant) clinical characteristics of patients enrolled in the study
  2. IV intravenous infusion, ATG anti-thymocyte globulin
  3. aDisease duration from first non-Raynaud’s phenomenon clinical manifestation until transplant
  4. bPatients with severe heart involvement were excluded from transplant